Inhibitors of influenza viruses replication

US9051319B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Paul S. Charifson · Framingham, US
• Michael P. Clark · Maineville, US
• Upul K. Bandarage · Lexington, US
• Randy S. Bethiel · Bedford, US
• Michael Boyd · Winchester, US
• Ioana Davies · Arlington, US
• Hongbo Deng · Southborough, US
• John P. Duffy · Westborough, US
• Luc Farmer · Foxborough, US
• Huai Gao · Arlington, US
• Wenxin Gu · Concord, US
• Joseph M. Kennedy · Walpole, US
• Brian Ledford · Attleboro, US
• Mark Ledeboer · Acton, US
• Francois Maltais · Somerville, US
• Emanuele Perola · Cambridge, US
• Tiansheng Wang · Concord, US

Key dates

• Filing date: Dec 6, 2013
• Grant date: Jun 9, 2015
• Expiry date: Dec 6, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.